. 2021 Aug 3:1–10. doi: 10.1159/000517380

Table 4.

Comparison of the parameters of patients according to chronic neurological disease

	PD (n = 98)	HA (n = 158)	MS (n = 126)	EP (n = 67)	PNP (n = 60)	CVD (n = 68)	p value
Age	65±11^a	39±12^b	38±10^b	47±17^c	61±12^a, ^d	60±15^d	0.0001**
Gender (F/M)	46/52^a	124/34^c	81/45^b	25/42^a	36/24^a, ^b, ^c	40/28^a, ^b, ^c	0.0001**
Comorbid diseases, %	61^a	36^b	20^c	45^a, ^b	70^a	79^a	0.0001**
Contact with COVID-19 patient, %	7^a	31^b	19^c	40^b	17^{a, b, c}	29^b, ^c	0.0001**
Diagnosis of COVID-19, %	5^a	19^b	15^b		13^a, ^b	9^ab	0.001**
DIT, %	32^a	28^ab	20^b	10^b	63^c	56^c	0.0001**
WHOQOL-BREF			59±23^b	55±19^a, ^b
Physical	48±20^a	49±17^a			36±14^c	44±14^c	0.0001**
Mental	51±1	48±15	55±19	55±16	43±16	45±13	0.001*
Social	39±21	45±21	51±24	48±23	41±19	44±17	0.002*
Environmental	66±16	62±16	61±19	63±16	46±13	54±14	0.0001**
IES-R total score	25±16^a	46±18^b	37±18^c	48±16^b	49±18^b	53±15^b	0.0001**
Intrusion	8±6	15.8±7	12±7	16.7±7	17±7	19±6	0.0001
Avoidance	10±5	18.3±6	16±6	19.5±5	18±6	21±5	0.0001
Hyperarousal	7±5	12.2±6	9±5	11.9±4	13±5	13±4	0.0001

WHOQOL-BREF, the World Health Organization Quality of Life short form; IES-R, Impact of Event Scale − Revised; DIT, distribution of treatment; COVID-19, coronavirus disease 2019; PD, Parkinson's disease; HA, headache; MS, multiple sclerosis; EP, epilepsy; PNP, polyneuropathy; CVD, cerebrovascular disease. * p < 0.05. ** p < 0.001. ^a–d p < 0.05, data were analyzed for various chronic neurological diseases by variance ANOVA with post hoc Fisher's least significant difference (LSD) tests.